New EU HTA System ‘Must Be Well Resourced’
Executive Summary
To ensure that the EU’s new regulation on health technology assessment is a success, resources must be made available and member states must start planning now before implementation in 2025.
You may also be interested in...
The Implications Of The New EU HTA Regulation For Companies
Legal and industry expert Alexander Natz sets out key questions and answers to help companies prepare for new EU regulations on health technology assessments, one of the biggest developments to affect the pharmaceutical industry in over a decade.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.